Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Dogwood Therapeutics released a corporate presentation detailing its non-opioid pain and neuropathy drug pipeline. Key focus is Halneuron (tetrodotoxin) for chemotherapy-induced neuropathic pain, with Phase 2b data expected in Fall 2026 and an FDA submission targeted for Q4 2026. The company reported USD 13.2 million in cash as of March 31, 2026.

Dogwood outlined key 2026 milestones for Halneuron injection in chemotherapy-induced neuropathic pain, including a Phase 2b data readout in fall 2026. * The company targets an end-of-Phase 2 FDA submission in Q4 2026 for Halneuron in chemotherapy-induced neuropathic pain. * Halneuron is tetrodotoxin, a Nav1.7 sodium-channel blocker delivered by subcutaneous injection; management highlighted durable pain reduction signals in prior studies. * Phase 2b interim analysis used a >50% responder endpoint; projected sample size of 210 to 240 patients to maintain 80% to 85% power. * Dogwood reported USD 13.2 million cash on a March 31, 2026 pro forma basis; shares outstanding 33,629,553. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Dogwood outlined key 2026 milestones for Halneuron injection in chemotherapy-induced neuropathic pain, including a Phase 2b data readout in fall 2026. * The company targets an end-of-Phase 2 FDA submission in Q4 2026 for Halneuron in chemotherapy-induced neuropathic pain. * Halneuron is tetrodotoxin, a Nav1.7 sodium-channel blocker delivered by subcutaneous injection; management highlighted durable pain reduction signals in prior studies. * Phase 2b interim analysis used a >50% responder endpoint; projected sample size of 210 to 240 patients to maintain 80% to 85% power. * Dogwood reported USD 13.2 million cash on a March 31, 2026 pro forma basis; shares outstanding 33,629,553. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here